Medical Marijuana, Inc. announced that its subsidiary Kannaway® has officially entered the U.S. cannabinol (CBN) market with the release of two new CBN isolate products.
Not to be confused with cannabidiol (CBD), which has gained significant popularity over the past few years, CBN is another non-psychoactive cannabinoid found in the cannabis plant. Like the company’s full-spectrum CBD products, Kannaway’s CBN products are derived from all-natural hemp.
“We’re very excited to become one of the first major hemp-derived product producers to offer CBN,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “It is being researched in several different studies, including a 300 person study just announced on Oct. 28, for its potential sedation and sleep effects.”
The new CBN product line includes Kannaway Pure CBN Liquid and Kannaway Pure CBN Gel Capsules.
“Though it may be too soon to predict the growth potential for the CBN market, analysts at the Nutrition Business Journal predict that the sleep supplement market will grow 30.1 percent this year,” said Kannaway CEO Blake Schroeder. “We intend to continue to stay up-to-date with the most recent discoveries in cannabinoid research and offer our customers the latest, most popular ingredients available in sleep science and other categories.”